<DOC>
	<DOCNO>NCT00783393</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy ( overall response ) safety temozolomide Step 1 dose regimen approve US EU country ( 28 day cycle temozolomide 150 200 mg/m2 daily 5 consecutive day 23 day rest period ) patient anaplastic astrocytoma first relapse .</brief_summary>
	<brief_title>SCH 52365 Phase II Clinical Study : A Study Efficacy Safety Monotherapy With SCH 52365 Patients With First Relapsed Anaplastic Astrocytoma ( Study P03745 )</brief_title>
	<detailed_description />
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Subject must histologically confirm anaplastic astrocytoma tentorium first relapse , satisfy following : unequivocal evidence tumor recurrence aggravation MRI scan treatment initial onset ; lesion must measurable ; anaplastic astrocytoma diagnose histologically last pathological diagnostic test ( include initial diagnosis ) prior initial administration temozolomide ; tissue sample available Central Pathologic Reviewer ; pathologic diagnosis report studyconducting medical institution must available sponsor . MRIrelated criterion : MRI scan perform within 14 day initial temozolomide administration ; assessable tumor site confirm MRI ; dosage steroidal agent increase within 7 day MRI prior initial temozolomide administration , except postoperative subject first relapse ; MRI perform Principal Investigator 's study location designate radiology facility study . Age &gt; =18 year , either sex , inpatient outpatient . Use medically approve contraception method fertile subject . Karnofsky performance status &gt; =70 . Adequate clinically laboratory value obtain within 14 day initial temozolomide administration . Criteria regard treatment initial onset : tumor biopsy , regardless tumor resection initial diagnosis ; prior radiation therapy ; prior chemotherapy one nitrosoureacontaining regimen . Tumor may may surgically resect first relapse , residual measurable disease require . For subject surgical resection tumor first relapse : MRI scan must perform within 72 hour surgery . dose steroidal agent must reduce temozolomide administration . Life expectancy &gt; =12 week . Written inform consent obtain . History treatment dacarbazine . Subjects receive chemotherapy within 6 week initial temozolomide administration . Subjects receive interstitial radiotherapy stereotactic radiosurgery . Subjects complete radiotherapy within 12 week initial temozolomide administration . Surgery first relapse ( include biopsy ) within 1 week initial temozolomide administration . Subjects recover acute toxicity due previous therapy . Highrisk subject complication disease malignant tumor , require systemic administration antibiotic infection . Previous concurrent malignancy sit . Pregnant nursing woman . Women childbearing potential use effective method contraception . Subjects previously treat temozolomide . Participation ongoing clinical study , clinical study within 6 month initial temozolomide administration . Subjects find inappropriate study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>